Nov 2026· Cell Reports Medicine· pp.
103131
· 0 citations· 75 references
Medicine
TL;DR
DVX-panH5Nx confers superior protection against antigenically distinct H5N1 challenges spanning two decades of viral evolution, demonstrating that computationally designed multivalent antigen vaccines can overcome natural influenza diversification and provide a scalable strategy for pre-pandemic preparedness.
Abstract
Influenza A/H5Nx viruses continue to diversify and undergo gene reassortment as they infect avian and mammalian hosts worldwide. The severity of human infections varies substantially between different H5 clades and neuraminidase (NA) reassortants, creating unpredictable pandemic risk. Existing H5 vaccines, typically based on a single hemagglutinin (HA) strain, cannot keep pace with this natural variation. To address this problem, we computationally engineer HA, NA, and M2 antigens representing the global antigenic space of circulating H5Nx viruses, prioritizing N1 and N6 subtypes associated with the highest threat in humans. The resulting digitally immune-optimized mRNA vaccine, DVX-panH5Nx, elicits broad HA neutralization and NA inhibition across divergent clades in mice and ferrets. Compared to WHO candidate vaccine viruses (CVVs), DVX-panH5Nx confers superior protection against antigenically distinct H5N1 challenges spanning two decades of viral evolution, demonstrating that computationally designed multivalent antigen vaccines can overcome natural influenza diversification and provide a scalable strategy for pre-pandemic preparedness.
ABSTRACT Influenza A virus (IAV) zoonotic transmission and continuous evolution in multiple host species heighten the risk of emerging novel strains at the human-animal interface. Digitally immune-optimized hemagglutinin (HA), neuraminidase (NA), and matrix-2 (M2) vaccine antigens were engineered and combined as a sing...
J. D. Del Rosario, P. V. van Diemen, Simon D. W. Frost et al.· Journal of Virology· 0 citations
Background: Emerging and re-emerging infectious diseases pose a growing global threat, underscoring the need for vaccine platforms enabling rapid deployment and durable, broad protection. Although mRNA and viral vector vaccines transformed pandemic responses, limitations include waning immunity, restricted antigenic br...
Joshua Wiggins, Adthakorn Madapong, Eric A. Weaver· Vaccines· 0 citations
Influenza viruses have served as experimental vaccine vectors for more than three decades, combining such advantages as mucosal delivery, segmented reverse genetics and clinically established attenuation strategies. This review summarizes historical insights into vector design based on influenza A and B viruses and pro...
I. Isakova-Sivak, V. Matyushenko, Larisa Rudenko· Virology· 0 citations
This multi-epitope DNA vaccine elicited cross-protective immunity against influenza A/H1N1 and A/H3N2 by targeting conserved HA and PA epitopes, supporting its potential as a candidate for universal influenza vaccine development.
K. Barkhordari, F. Rezaei, V. Salimi et al.· Iranian Journal of Microbiol...· 0 citations
Seasonal influenza vaccines require annual reformulation due to antigenic drift and provide suboptimal protection. Here, we evaluate self-amplifying mRNA (samRNA) vaccines encoding chimeric (cHA) and mosaic (mHA) hemagglutinins representing influenza A virus HA phylogenetic groups 1 and 2. Following prime-boost immuniz...
A. Abbad, Temima Yellin, J. Carreño et al.· Cell Reports· 0 citations
Seasonal influenza vaccines are reformulated annually to match circulating strains of influenza A/H1N1, A/H3N2, and B, yet their efficacy remains fundamentally limited to neutralizing antibody responses against the strain-specific but highly variable hemagglutinin (HA) head domain. This limitation is compounded by pre-...
Arini Arsana, Wan-Di Zhu, Sang-Moo Kang et al.· Virology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.